{{NotChineseTitle|time=2015-12-14T04:36:23+00:00}}
{{medical}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458273983
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD4受体|CD4受体]]
<!-- Clinical data -->
| tradename =  Trogarzo
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 未知
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = [[靜脈注射|靜脈注射]]
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 680188-33-4
| ATC_prefix = J05
| ATC_suffix = AX23
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LT369U66CE
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09575
| NIAID_ChemDB = 209859
| synonyms = Ibalizumab-uiyk、TMB-355,<ref>{{cite web |url=http://www.tmbinc.com/?page_id=23 |title=Ibalizumab (TMB-355) |publisher=TaiMed Biologics |date=2009-09-09 |archive-url=https://web.archive.org/web/20090820202400/http://www.tmbinc.com/?page_id=23 |archive-date=2009-08-20 |accessdate=2019-12-24 |dead-url=yes }}</ref> TNX-355
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Ibalizumab'''，是一種非免疫抑制性的[[單克隆抗體|-{zh-hant:單株抗體;zh-hans:单克隆抗体;}-]]，属于[[融合抑制剂|融合抑制剂]]类[[靶向药物|靶向药物]]。本品會與[[人類免疫缺陷病毒|人類免疫缺陷病毒]]（HIV）的主要受體[[CD4受体|CD4]]結合<ref name="pmid19015347">{{cite journal|title=Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=19015347|date=February 2009|journal=Antimicrobial Agents and Chemotherapy|issue=2|doi=10.1128/AAC.00942-08|volume=53|pages=450–7|pmc=2630626|pmid=19015347|vauthors=Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST|access-date=2019-12-24|archive-date=2019-12-10|archive-url=https://web.archive.org/web/20191210104135/http://aac.asm.org/cgi/pmidlookup?view=long&pmid=19015347|dead-url=yes}}</ref>，進而抑制[[病毒|病毒]]進入細胞<ref>{{cite web|title=TNX-355 fact sheet|url=http://www.aidsmeds.com/archive/TNX-355_1631.shtml|date=2006-08-25|publisher=AIDSmeds.com|accessdate=2019-12-24|archive-date=2015-09-06|archive-url=https://web.archive.org/web/20150906221023/http://www.aidsmeds.com/archive/TNX-355_1631.shtml|dead-url=no}}</ref>。

== 藥理學 ==
Ibalizumab為一種非免疫抑制性的人源化鼠源性[[IgG4|IgG4]][[單克隆抗體|-{zh-hant:單株抗體;zh-hans:单克隆抗体;}-]]，属于[[融合抑制剂|融合抑制剂]]类[[靶向药物|靶向药物]]<ref name=":0">{{Cite journal|title=Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1|url=https://doi.org/10.1056/NEJMoa1711460|last=Emu|first=Brinda|last2=Fessel|first2=Jeffrey|date=2018-08-16|journal=New England Journal of Medicine|issue=7|doi=10.1056/NEJMoa1711460|volume=379|pages=645–654|issn=0028-4793|pmid=30110589|last3=Schrader|first3=Shannon|last4=Kumar|first4=Princy|last5=Richmond|first5=Gary|last6=Win|first6=Sandra|last7=Weinheimer|first7=Steven|last8=Marsolais|first8=Christian|last9=Lewis|first9=Stanley}}</ref>。本品會與CD4受體的胞外結合區競爭性結合，進而阻擋HIV病毒上的{{tsl|en|gp120||gp120}}[[醣蛋白|醣蛋白]]與CD4結合，進而阻斷病毒進入細胞的過程<ref name=":0" />。

本品與CD4和[[MHC2類分子|MHC II]]分子的結合區不同，目前顯示不會干擾CD4相關的免疫反應<ref name=":0" />。且因屬於IgG4，較不易引起[[ADCC作用|ADCC作用]]<ref name=":0" />。

== 適應症 ==
本品的第三期試驗顯示在多重抗藥性[[HIV-1|HIV-1]]感染患者，本品可以有效降低病毒量<ref name=":0" />，且藥物耐受性良好<ref>{{cite journal|title=Forty-eight-week Safety and Efficacy On-treatment Analysis of Ibalizumab in Patients with Multi-drug Resistant HIV-1.|date=October 2017|journal=Open Forum Infectious Diseases|issue=suppl 1|doi=10.1093/ofid/ofx162.093|volume=4|pages=S38–S39)|pmc=5632088|vauthors=Emu B, Fessel WJ, Schrader S, Kumar PN, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S}}</ref>。2018年3月6日，FDA核准Ibalizumab用於多重抗藥性HIV-1患者治療<ref name="FDA">{{cite web|title=Ibalizumab|url=https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=321910|date=2018-03-07|accessdate=2019-12-24|archive-date=2019-07-11|archive-url=https://web.archive.org/web/20190711144920/https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=321910|dead-url=yes}}</ref>。

== 歷史 ==
本品最早由[[何大一|何大一]]教授指導下，於{{tsl|en|Aaron Diamond AIDS Research Center|艾倫·戴蒙德愛滋病研究中心}}與[[Tanox|Tanox]]藥廠開發而成。並由Tanox公司完成第一期與第二期臨床試驗，確認藥物的安全性。後來[[基因泰克|基因泰克]]（Genetech）公司收購Tanox股權時，2007年9月將本品專利權售予[[臺灣|台灣]]的[[宇昌生技|宇昌生技]]（今[[中裕新藥|中裕新藥公司]]）。2016年，本品完成第三期臨床試驗，BLA送件於2017年完成，並於2018年得到美國FDA藥證<ref>{{cite news|url=http://seekingalpha.com/article/47462-genentech-partners-with-taiwan-company-on-aids-drug|title=Genentech Partners with Taiwan Company on AIDS Drug|work=Seeking Alpha|date=2007-09-18|accessdate=2019-12-24|archive-date=2016-03-03|archive-url=https://web.archive.org/web/20160303183016/http://seekingalpha.com/article/47462-genentech-partners-with-taiwan-company-on-aids-drug|dead-url=no}}</ref><ref>{{cite news|url=http://www.taipeitimes.com/News/biz/archives/2007/09/15/2003378907|title=Government pushes biotech industry|work=Taipei Times|date=2007-09-15|accessdate=2019-12-24|archive-date=2019-08-11|archive-url=https://web.archive.org/web/20190811175551/http://www.taipeitimes.com/News/biz/archives/2007/09/15/2003378907|dead-url=no}}</ref><ref>{{cite news|url=http://www.biohouston.org/en/rel/?18|title=Tanox's AIDS Drug Survives|work=BioHouston|date=2008-04-11|archive-url=https://web.archive.org/web/20110725073913/http://www.biohouston.org/en/rel/?18|archive-date=2011-07-25|accessdate=2019-12-24|dead-url=yes}}</ref>。2019年9月，本品獲歐盟執委會核准上市<ref>{{Cite web|title=賀！中裕(4147)愛滋病新藥Trogarzo靜脈注射劑型正式獲歐盟執委會 EC新藥上市核准 - 生技投資第一站-Genet 觀點|url=http://www.genetinfo.com/investment/featured/item/30707.html|accessdate=2019-12-24|work=www.genetinfo.com|language=zh-TW|archive-date=2020-01-28|archive-url=https://web.archive.org/web/20200128020751/http://www.genetinfo.com/investment/featured/item/30707.html|dead-url=no}}</ref>。

== 給藥 ==
本品透過靜脈輸注給藥，每14日一劑。可與合適的抗病毒藥物共同給藥<ref name="Medscape">{{cite web|title=FDA Approves Ibalizumab for Multidrug-Resistant HIV-1|url=https://www.medscape.com/viewarticle/893512|date=2018-03-07|accessdate=2019-12-24|archive-date=2019-10-13|archive-url=https://web.archive.org/web/20191013215540/https://www.medscape.com/viewarticle/893512|dead-url=no}}</ref>。

== 參考文獻 ==
{{reflist}}

{{抗逆转录病毒药物}}

{{DEFAULTSORT:Ibalizumab}}

[[Category:单克隆抗体类|Category:单克隆抗体类]]
[[Category:治疗用抗体|Category:治疗用抗体]]
[[Category:融合抑制剂|Category:融合抑制剂]]